share_log

HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

HC Wainwright & Co.维持对Lyell Immunopharma的买入,将目标股价下调至6美元
Benzinga ·  02/29 15:21

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $8 to $6.

HC Wainwright & Co. 分析师米切尔·卡普尔维持莱尔免疫药业(纳斯达克股票代码:LYEL)的买入并将目标股价从8美元下调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发